SlideShare a Scribd company logo

160929 roche presentation molecule to business

S
SMBBV

Roche, How to deal with the affordability of oncology drugs?From personalised medicine to personalised reimbursement models. Presentation by Jeroen van Dijk during 'From Molecule to Business' event by SMB Life Sciences and Health Valley at NovioTechCampus, Nijmegen, The Netherlands on September 29, 2016.

1 of 17
Download to read offline
How to deal with the affordability of oncology drugs?
From personalised medicine to personalised
reimbursement models
Jeroen van Dijk, Sales Director, Roche Nederland
September 29th 2016
Doing now what patients
need next
Political and public discussions
Bron: www.minvws.nl; KWF, 2015
The Netherlands compared to other EU
countries
Source: Healthcare costs of cancer per person in European Union (Luengo-Fernandez et al - Lancet Oncology, 2013)
Spending over the last years
Out-patient vs hospital setting
Outpatient drugs
Hospital drugs
Spending in bln €
Drug expenses in 2015
Health care expenses 2015 Increase
Health care budget (Budget Kader
Zorg)
€73 billion -
Drugs (total) €5 billion 6%
Inpatient drugs €2.06 billion 6%
‘Expensive’ inpatient drugs €1.62 billion 9%
‘Expensive’ oncology drugs €810 million 15%
Source: Farminform, 2016

Recommended

Multi-Indication Pricing: Do we want it? Can we operationalize it?
Multi-Indication Pricing: Do we want it? Can we operationalize it?Multi-Indication Pricing: Do we want it? Can we operationalize it?
Multi-Indication Pricing: Do we want it? Can we operationalize it?Office of Health Economics
 
“Multi-indication Pricing: Do we want it? Can we operationalize it?”
“Multi-indication Pricing: Do we want it? Can we operationalize it?”“Multi-indication Pricing: Do we want it? Can we operationalize it?”
“Multi-indication Pricing: Do we want it? Can we operationalize it?”Office of Health Economics
 
Ponencia 08 pharmacist_uk_steele_j
Ponencia 08 pharmacist_uk_steele_jPonencia 08 pharmacist_uk_steele_j
Ponencia 08 pharmacist_uk_steele_jz15sefap
 
Using MCDA for HTA, Opportunities, Challenges and Possible Ways Forward
Using MCDA for HTA, Opportunities, Challenges and Possible Ways ForwardUsing MCDA for HTA, Opportunities, Challenges and Possible Ways Forward
Using MCDA for HTA, Opportunities, Challenges and Possible Ways ForwardOffice of Health Economics
 
EUPATI 2013 Conference: Patient involvement in medicines R&D: Bringing to li...
EUPATI 2013 Conference: Patient involvement in medicines R&D: Bringing to li...EUPATI 2013 Conference: Patient involvement in medicines R&D: Bringing to li...
EUPATI 2013 Conference: Patient involvement in medicines R&D: Bringing to li...EUPATI
 
EUPATI 2013 Conference: Building Knowledge & Competences for Patients’ Involv...
EUPATI 2013 Conference: Building Knowledge & Competences for Patients’ Involv...EUPATI 2013 Conference: Building Knowledge & Competences for Patients’ Involv...
EUPATI 2013 Conference: Building Knowledge & Competences for Patients’ Involv...EUPATI
 

More Related Content

What's hot

Changes in patient organisations - and how this changes the medical world
Changes in patient organisations - and how this changes the medical worldChanges in patient organisations - and how this changes the medical world
Changes in patient organisations - and how this changes the medical worldjangeissler
 
EUPATI 2013 Conference: Vision on Patient involvement in medicines R&D: Here...
EUPATI 2013 Conference: Vision on Patient involvement in medicines R&D: Here...EUPATI 2013 Conference: Vision on Patient involvement in medicines R&D: Here...
EUPATI 2013 Conference: Vision on Patient involvement in medicines R&D: Here...EUPATI
 
Multi-Indication Pricing: Pros, Cons and Applicability to the UK
Multi-Indication Pricing: Pros, Cons and Applicability to the UKMulti-Indication Pricing: Pros, Cons and Applicability to the UK
Multi-Indication Pricing: Pros, Cons and Applicability to the UKKerry Sheppard
 
Good practices in patient involvement in HTA
Good practices in patient involvement in HTAGood practices in patient involvement in HTA
Good practices in patient involvement in HTAEUPATI
 
Data Governance for Real-World Evidence: Cross-country differences and recomm...
Data Governance for Real-World Evidence: Cross-country differences and recomm...Data Governance for Real-World Evidence: Cross-country differences and recomm...
Data Governance for Real-World Evidence: Cross-country differences and recomm...Office of Health Economics
 
The Value of Knowing and Knowing the Value: Improving the Health Technology A...
The Value of Knowing and Knowing the Value: Improving the Health Technology A...The Value of Knowing and Knowing the Value: Improving the Health Technology A...
The Value of Knowing and Knowing the Value: Improving the Health Technology A...Office of Health Economics
 
Making value-based pricing a reality – the case for multi-indication pricing
Making value-based pricing a reality – the case for multi-indication pricing Making value-based pricing a reality – the case for multi-indication pricing
Making value-based pricing a reality – the case for multi-indication pricing Office of Health Economics
 
Tripartite dimension of interaction of patients, regulators and industry (Jan...
Tripartite dimension of interaction of patients, regulators and industry (Jan...Tripartite dimension of interaction of patients, regulators and industry (Jan...
Tripartite dimension of interaction of patients, regulators and industry (Jan...jangeissler
 
Are Existing HTA Requirements Inadequate for Establishing Value for Potential...
Are Existing HTA Requirements Inadequate for Establishing Value for Potential...Are Existing HTA Requirements Inadequate for Establishing Value for Potential...
Are Existing HTA Requirements Inadequate for Establishing Value for Potential...Office of Health Economics
 
How can HTA’s in Asia respond to Increased Clinical Uncertainty: the potentia...
How can HTA’s in Asia respond to Increased Clinical Uncertainty: the potentia...How can HTA’s in Asia respond to Increased Clinical Uncertainty: the potentia...
How can HTA’s in Asia respond to Increased Clinical Uncertainty: the potentia...Office of Health Economics
 
Jens Heisterberg - Patient involvement in drug development and licensing
Jens Heisterberg - Patient involvement in drug development and licensingJens Heisterberg - Patient involvement in drug development and licensing
Jens Heisterberg - Patient involvement in drug development and licensingkoradk
 
Education of patients (advocates) on R&D: European Patients’ Academy EUPATI...
Education of patients (advocates) on R&D: European Patients’ Academy EUPATI...Education of patients (advocates) on R&D: European Patients’ Academy EUPATI...
Education of patients (advocates) on R&D: European Patients’ Academy EUPATI...jangeissler
 
Steffen Thirstrup - Patient involvement when, why, who?
Steffen Thirstrup - Patient involvement when, why, who?Steffen Thirstrup - Patient involvement when, why, who?
Steffen Thirstrup - Patient involvement when, why, who?koradk
 
Measuring Medicine Prices
Measuring Medicine PricesMeasuring Medicine Prices
Measuring Medicine PricesMeTApresents
 
How Effective is the Public in Influencing HTA Decisions?
How Effective is the Public in Influencing HTA Decisions?How Effective is the Public in Influencing HTA Decisions?
How Effective is the Public in Influencing HTA Decisions?Kathi Apostolidis
 
The Networked Patient Group: How technology changes the face of patient advocacy
The Networked Patient Group: How technology changes the face of patient advocacyThe Networked Patient Group: How technology changes the face of patient advocacy
The Networked Patient Group: How technology changes the face of patient advocacyjangeissler
 
Why RWE Matters to Payers: Incorporating RWE in Health Economic Analysis to M...
Why RWE Matters to Payers: Incorporating RWE in Health Economic Analysis to M...Why RWE Matters to Payers: Incorporating RWE in Health Economic Analysis to M...
Why RWE Matters to Payers: Incorporating RWE in Health Economic Analysis to M...Office of Health Economics
 
Patients’ voice in access decisions
Patients’ voice in access decisionsPatients’ voice in access decisions
Patients’ voice in access decisionsEUPATI
 

What's hot (20)

Changes in patient organisations - and how this changes the medical world
Changes in patient organisations - and how this changes the medical worldChanges in patient organisations - and how this changes the medical world
Changes in patient organisations - and how this changes the medical world
 
EUPATI 2013 Conference: Vision on Patient involvement in medicines R&D: Here...
EUPATI 2013 Conference: Vision on Patient involvement in medicines R&D: Here...EUPATI 2013 Conference: Vision on Patient involvement in medicines R&D: Here...
EUPATI 2013 Conference: Vision on Patient involvement in medicines R&D: Here...
 
Multi-Indication Pricing: Pros, Cons and Applicability to the UK
Multi-Indication Pricing: Pros, Cons and Applicability to the UKMulti-Indication Pricing: Pros, Cons and Applicability to the UK
Multi-Indication Pricing: Pros, Cons and Applicability to the UK
 
Good practices in patient involvement in HTA
Good practices in patient involvement in HTAGood practices in patient involvement in HTA
Good practices in patient involvement in HTA
 
Data Governance for Real-World Evidence: Cross-country differences and recomm...
Data Governance for Real-World Evidence: Cross-country differences and recomm...Data Governance for Real-World Evidence: Cross-country differences and recomm...
Data Governance for Real-World Evidence: Cross-country differences and recomm...
 
The Value of Knowing and Knowing the Value: Improving the Health Technology A...
The Value of Knowing and Knowing the Value: Improving the Health Technology A...The Value of Knowing and Knowing the Value: Improving the Health Technology A...
The Value of Knowing and Knowing the Value: Improving the Health Technology A...
 
Making value-based pricing a reality – the case for multi-indication pricing
Making value-based pricing a reality – the case for multi-indication pricing Making value-based pricing a reality – the case for multi-indication pricing
Making value-based pricing a reality – the case for multi-indication pricing
 
Tripartite dimension of interaction of patients, regulators and industry (Jan...
Tripartite dimension of interaction of patients, regulators and industry (Jan...Tripartite dimension of interaction of patients, regulators and industry (Jan...
Tripartite dimension of interaction of patients, regulators and industry (Jan...
 
Jornadas #PatientInHTA · Iñaki Imaz
Jornadas #PatientInHTA · Iñaki ImazJornadas #PatientInHTA · Iñaki Imaz
Jornadas #PatientInHTA · Iñaki Imaz
 
Are Existing HTA Requirements Inadequate for Establishing Value for Potential...
Are Existing HTA Requirements Inadequate for Establishing Value for Potential...Are Existing HTA Requirements Inadequate for Establishing Value for Potential...
Are Existing HTA Requirements Inadequate for Establishing Value for Potential...
 
How can HTA’s in Asia respond to Increased Clinical Uncertainty: the potentia...
How can HTA’s in Asia respond to Increased Clinical Uncertainty: the potentia...How can HTA’s in Asia respond to Increased Clinical Uncertainty: the potentia...
How can HTA’s in Asia respond to Increased Clinical Uncertainty: the potentia...
 
Jens Heisterberg - Patient involvement in drug development and licensing
Jens Heisterberg - Patient involvement in drug development and licensingJens Heisterberg - Patient involvement in drug development and licensing
Jens Heisterberg - Patient involvement in drug development and licensing
 
Education of patients (advocates) on R&D: European Patients’ Academy EUPATI...
Education of patients (advocates) on R&D: European Patients’ Academy EUPATI...Education of patients (advocates) on R&D: European Patients’ Academy EUPATI...
Education of patients (advocates) on R&D: European Patients’ Academy EUPATI...
 
Steffen Thirstrup - Patient involvement when, why, who?
Steffen Thirstrup - Patient involvement when, why, who?Steffen Thirstrup - Patient involvement when, why, who?
Steffen Thirstrup - Patient involvement when, why, who?
 
Measuring Medicine Prices
Measuring Medicine PricesMeasuring Medicine Prices
Measuring Medicine Prices
 
How Effective is the Public in Influencing HTA Decisions?
How Effective is the Public in Influencing HTA Decisions?How Effective is the Public in Influencing HTA Decisions?
How Effective is the Public in Influencing HTA Decisions?
 
The Networked Patient Group: How technology changes the face of patient advocacy
The Networked Patient Group: How technology changes the face of patient advocacyThe Networked Patient Group: How technology changes the face of patient advocacy
The Networked Patient Group: How technology changes the face of patient advocacy
 
Why RWE Matters to Payers: Incorporating RWE in Health Economic Analysis to M...
Why RWE Matters to Payers: Incorporating RWE in Health Economic Analysis to M...Why RWE Matters to Payers: Incorporating RWE in Health Economic Analysis to M...
Why RWE Matters to Payers: Incorporating RWE in Health Economic Analysis to M...
 
Patients’ voice in access decisions
Patients’ voice in access decisionsPatients’ voice in access decisions
Patients’ voice in access decisions
 
Towse future of CER in US
Towse future of CER in USTowse future of CER in US
Towse future of CER in US
 

Similar to 160929 roche presentation molecule to business

Orphan Drugs – High Prices: Is there a Way Forward?
Orphan Drugs – High Prices: Is there a Way Forward?Orphan Drugs – High Prices: Is there a Way Forward?
Orphan Drugs – High Prices: Is there a Way Forward?Office of Health Economics
 
Budget Impact and Expenditure Caps: Potential or Pitfall?
Budget Impact and Expenditure Caps: Potential or Pitfall?Budget Impact and Expenditure Caps: Potential or Pitfall?
Budget Impact and Expenditure Caps: Potential or Pitfall?Office of Health Economics
 
Does Price Discrimination Have a Place in Pharmaceutical Pricing in Developin...
Does Price Discrimination Have a Place in Pharmaceutical Pricing in Developin...Does Price Discrimination Have a Place in Pharmaceutical Pricing in Developin...
Does Price Discrimination Have a Place in Pharmaceutical Pricing in Developin...Office of Health Economics
 
Joint Rare Diseases / Orphan Medicinal Products Task Force
Joint Rare Diseases / Orphan Medicinal Products Task ForceJoint Rare Diseases / Orphan Medicinal Products Task Force
Joint Rare Diseases / Orphan Medicinal Products Task ForceDutch Orphan Drug Network
 
1115 aine carroll clinical leaders forum nhc integrated care turning healthca...
1115 aine carroll clinical leaders forum nhc integrated care turning healthca...1115 aine carroll clinical leaders forum nhc integrated care turning healthca...
1115 aine carroll clinical leaders forum nhc integrated care turning healthca...investnethealthcare
 
The Impact Global Pharma Cost Containment Methods in APAC
The Impact Global Pharma Cost Containment Methods in APACThe Impact Global Pharma Cost Containment Methods in APAC
The Impact Global Pharma Cost Containment Methods in APACQuintilesIMS Asia Pacific
 
Personalized Medicine: Uptake Challenges
Personalized Medicine: Uptake ChallengesPersonalized Medicine: Uptake Challenges
Personalized Medicine: Uptake Challengesexecutiveinsight
 
OHE Lecturing for Professional Training at International Centre of Parliament...
OHE Lecturing for Professional Training at International Centre of Parliament...OHE Lecturing for Professional Training at International Centre of Parliament...
OHE Lecturing for Professional Training at International Centre of Parliament...Office of Health Economics
 
Value based healthcare 2020
Value based healthcare 2020Value based healthcare 2020
Value based healthcare 2020Future Agenda
 
Approaches to Evaluating New Medicines in France, Germany and England
Approaches to Evaluating New Medicines in France, Germany and EnglandApproaches to Evaluating New Medicines in France, Germany and England
Approaches to Evaluating New Medicines in France, Germany and EnglandOffice of Health Economics
 
Creating collaborative systems to address orphan drugs in a sustainable way –...
Creating collaborative systems to address orphan drugs in a sustainable way –...Creating collaborative systems to address orphan drugs in a sustainable way –...
Creating collaborative systems to address orphan drugs in a sustainable way –...Dutch Orphan Drug Network
 
Establishing a Fair Price for an Orphan Drug by Mikel Berdud et al.
Establishing a Fair Price for an Orphan Drug by Mikel Berdud et al.Establishing a Fair Price for an Orphan Drug by Mikel Berdud et al.
Establishing a Fair Price for an Orphan Drug by Mikel Berdud et al.Office of Health Economics
 
Value based healthcare
Value based healthcareValue based healthcare
Value based healthcareAsem Shadid
 
Investigation of the accessibility and affordability of medicines in speciali...
Investigation of the accessibility and affordability of medicines in speciali...Investigation of the accessibility and affordability of medicines in speciali...
Investigation of the accessibility and affordability of medicines in speciali...Cornelis Jan Diepeveen
 
Healthcarecosts conv vs CAM GP's BMJOpenSept2014Baars
Healthcarecosts conv vs CAM GP's BMJOpenSept2014BaarsHealthcarecosts conv vs CAM GP's BMJOpenSept2014Baars
Healthcarecosts conv vs CAM GP's BMJOpenSept2014BaarsMarco Ephraïm
 

Similar to 160929 roche presentation molecule to business (20)

Orphan Drugs – High Prices: Is there a Way Forward?
Orphan Drugs – High Prices: Is there a Way Forward?Orphan Drugs – High Prices: Is there a Way Forward?
Orphan Drugs – High Prices: Is there a Way Forward?
 
Budget Impact and Expenditure Caps: Potential or Pitfall?
Budget Impact and Expenditure Caps: Potential or Pitfall?Budget Impact and Expenditure Caps: Potential or Pitfall?
Budget Impact and Expenditure Caps: Potential or Pitfall?
 
Does Price Discrimination Have a Place in Pharmaceutical Pricing in Developin...
Does Price Discrimination Have a Place in Pharmaceutical Pricing in Developin...Does Price Discrimination Have a Place in Pharmaceutical Pricing in Developin...
Does Price Discrimination Have a Place in Pharmaceutical Pricing in Developin...
 
The value of generics and biosimilar drugs
The value of generics and biosimilar drugsThe value of generics and biosimilar drugs
The value of generics and biosimilar drugs
 
Joint Rare Diseases / Orphan Medicinal Products Task Force
Joint Rare Diseases / Orphan Medicinal Products Task ForceJoint Rare Diseases / Orphan Medicinal Products Task Force
Joint Rare Diseases / Orphan Medicinal Products Task Force
 
1115 aine carroll clinical leaders forum nhc integrated care turning healthca...
1115 aine carroll clinical leaders forum nhc integrated care turning healthca...1115 aine carroll clinical leaders forum nhc integrated care turning healthca...
1115 aine carroll clinical leaders forum nhc integrated care turning healthca...
 
Abpi rd conference_towse_ 20_nov_2014
Abpi rd conference_towse_ 20_nov_2014Abpi rd conference_towse_ 20_nov_2014
Abpi rd conference_towse_ 20_nov_2014
 
The Impact Global Pharma Cost Containment Methods in APAC
The Impact Global Pharma Cost Containment Methods in APACThe Impact Global Pharma Cost Containment Methods in APAC
The Impact Global Pharma Cost Containment Methods in APAC
 
Personalized Medicine: Uptake Challenges
Personalized Medicine: Uptake ChallengesPersonalized Medicine: Uptake Challenges
Personalized Medicine: Uptake Challenges
 
OHE Lecturing for Professional Training at International Centre of Parliament...
OHE Lecturing for Professional Training at International Centre of Parliament...OHE Lecturing for Professional Training at International Centre of Parliament...
OHE Lecturing for Professional Training at International Centre of Parliament...
 
Value based healthcare 2020
Value based healthcare 2020Value based healthcare 2020
Value based healthcare 2020
 
Approaches to Evaluating New Medicines in France, Germany and England
Approaches to Evaluating New Medicines in France, Germany and EnglandApproaches to Evaluating New Medicines in France, Germany and England
Approaches to Evaluating New Medicines in France, Germany and England
 
Drug Purchasing & Pricing : industry perspective
Drug Purchasing & Pricing : industry perspectiveDrug Purchasing & Pricing : industry perspective
Drug Purchasing & Pricing : industry perspective
 
Creating collaborative systems to address orphan drugs in a sustainable way –...
Creating collaborative systems to address orphan drugs in a sustainable way –...Creating collaborative systems to address orphan drugs in a sustainable way –...
Creating collaborative systems to address orphan drugs in a sustainable way –...
 
Establishing a Fair Price for an Orphan Drug by Mikel Berdud et al.
Establishing a Fair Price for an Orphan Drug by Mikel Berdud et al.Establishing a Fair Price for an Orphan Drug by Mikel Berdud et al.
Establishing a Fair Price for an Orphan Drug by Mikel Berdud et al.
 
Value based healthcare
Value based healthcareValue based healthcare
Value based healthcare
 
Investigation of the accessibility and affordability of medicines in speciali...
Investigation of the accessibility and affordability of medicines in speciali...Investigation of the accessibility and affordability of medicines in speciali...
Investigation of the accessibility and affordability of medicines in speciali...
 
Patient involvement
Patient involvementPatient involvement
Patient involvement
 
Cadth 2015 e6 1 corner
Cadth 2015 e6 1 cornerCadth 2015 e6 1 corner
Cadth 2015 e6 1 corner
 
Healthcarecosts conv vs CAM GP's BMJOpenSept2014Baars
Healthcarecosts conv vs CAM GP's BMJOpenSept2014BaarsHealthcarecosts conv vs CAM GP's BMJOpenSept2014Baars
Healthcarecosts conv vs CAM GP's BMJOpenSept2014Baars
 

More from SMBBV

190228 student project science food and health 2018 radboud university (smb m...
190228 student project science food and health 2018 radboud university (smb m...190228 student project science food and health 2018 radboud university (smb m...
190228 student project science food and health 2018 radboud university (smb m...SMBBV
 
190228 pitch student group 3 microresonator platform to detect cancer (smb me...
190228 pitch student group 3 microresonator platform to detect cancer (smb me...190228 pitch student group 3 microresonator platform to detect cancer (smb me...
190228 pitch student group 3 microresonator platform to detect cancer (smb me...SMBBV
 
190228 pitch student group 1 new crystals cheaper medicines (smb meeting)
190228 pitch student group 1 new crystals cheaper medicines (smb meeting)190228 pitch student group 1 new crystals cheaper medicines (smb meeting)
190228 pitch student group 1 new crystals cheaper medicines (smb meeting)SMBBV
 
190228 pitch student groep 4 nirly fresh (smb meeting)
190228 pitch student groep 4 nirly fresh (smb meeting)190228 pitch student groep 4 nirly fresh (smb meeting)
190228 pitch student groep 4 nirly fresh (smb meeting)SMBBV
 
190228 pitch student groep 2 diy on cochlear implants (smb meeting)
190228 pitch student groep 2 diy on cochlear implants (smb meeting)190228 pitch student groep 2 diy on cochlear implants (smb meeting)
190228 pitch student groep 2 diy on cochlear implants (smb meeting)SMBBV
 
190129 presentatie stat stories lonneke opsteegh (smb meeting)
190129 presentatie stat stories   lonneke opsteegh (smb meeting)190129 presentatie stat stories   lonneke opsteegh (smb meeting)
190129 presentatie stat stories lonneke opsteegh (smb meeting)SMBBV
 
190129 presentatie onder de bomen floris heukelom (smb meeting)
190129 presentatie onder de bomen   floris heukelom (smb meeting)190129 presentatie onder de bomen   floris heukelom (smb meeting)
190129 presentatie onder de bomen floris heukelom (smb meeting)SMBBV
 
190129 de groeiversneller oost nl (smb meeting)
190129 de groeiversneller oost nl (smb meeting)190129 de groeiversneller oost nl (smb meeting)
190129 de groeiversneller oost nl (smb meeting)SMBBV
 
190129 de groeiversneller oost nl (smb meeting)
190129 de groeiversneller oost nl (smb meeting)190129 de groeiversneller oost nl (smb meeting)
190129 de groeiversneller oost nl (smb meeting)SMBBV
 
180927 presentation dhl ali kocer (smb hv meeting)
180927 presentation dhl ali kocer (smb hv meeting)180927 presentation dhl ali kocer (smb hv meeting)
180927 presentation dhl ali kocer (smb hv meeting)SMBBV
 
180927 presentation enzyre waander van heerde (smb hv meeting)
180927 presentation enzyre waander van heerde (smb hv meeting)180927 presentation enzyre waander van heerde (smb hv meeting)
180927 presentation enzyre waander van heerde (smb hv meeting)SMBBV
 
180927 presentation tjoapack dexter tjoa (smb hv meeting)
180927 presentation tjoapack dexter tjoa (smb hv meeting)180927 presentation tjoapack dexter tjoa (smb hv meeting)
180927 presentation tjoapack dexter tjoa (smb hv meeting)SMBBV
 
180703 start updelta on tour slides smb meeting
180703 start updelta on tour slides smb meeting180703 start updelta on tour slides smb meeting
180703 start updelta on tour slides smb meetingSMBBV
 
180703 sit and heat slides smb meeting
180703 sit and heat slides smb meeting180703 sit and heat slides smb meeting
180703 sit and heat slides smb meetingSMBBV
 
180703 pink rf slides smb meeting
180703 pink rf slides smb meeting180703 pink rf slides smb meeting
180703 pink rf slides smb meetingSMBBV
 
180222 presentatie orikami bram ten teuling (smb meeting)
180222 presentatie orikami bram ten teuling (smb meeting)180222 presentatie orikami bram ten teuling (smb meeting)
180222 presentatie orikami bram ten teuling (smb meeting)SMBBV
 
180222 ru student presentation 4 nieuwe oren
180222 ru student presentation 4 nieuwe oren180222 ru student presentation 4 nieuwe oren
180222 ru student presentation 4 nieuwe orenSMBBV
 
180222 ru student presentation 3 low key urine_screening
180222 ru student presentation 3 low key urine_screening180222 ru student presentation 3 low key urine_screening
180222 ru student presentation 3 low key urine_screeningSMBBV
 
180222 ru student presentation 2 object detection for hemispatial neglect pat...
180222 ru student presentation 2 object detection for hemispatial neglect pat...180222 ru student presentation 2 object detection for hemispatial neglect pat...
180222 ru student presentation 2 object detection for hemispatial neglect pat...SMBBV
 
180222 ru student presentation 1 n ox measurement
180222 ru student presentation 1 n ox measurement180222 ru student presentation 1 n ox measurement
180222 ru student presentation 1 n ox measurementSMBBV
 

More from SMBBV (20)

190228 student project science food and health 2018 radboud university (smb m...
190228 student project science food and health 2018 radboud university (smb m...190228 student project science food and health 2018 radboud university (smb m...
190228 student project science food and health 2018 radboud university (smb m...
 
190228 pitch student group 3 microresonator platform to detect cancer (smb me...
190228 pitch student group 3 microresonator platform to detect cancer (smb me...190228 pitch student group 3 microresonator platform to detect cancer (smb me...
190228 pitch student group 3 microresonator platform to detect cancer (smb me...
 
190228 pitch student group 1 new crystals cheaper medicines (smb meeting)
190228 pitch student group 1 new crystals cheaper medicines (smb meeting)190228 pitch student group 1 new crystals cheaper medicines (smb meeting)
190228 pitch student group 1 new crystals cheaper medicines (smb meeting)
 
190228 pitch student groep 4 nirly fresh (smb meeting)
190228 pitch student groep 4 nirly fresh (smb meeting)190228 pitch student groep 4 nirly fresh (smb meeting)
190228 pitch student groep 4 nirly fresh (smb meeting)
 
190228 pitch student groep 2 diy on cochlear implants (smb meeting)
190228 pitch student groep 2 diy on cochlear implants (smb meeting)190228 pitch student groep 2 diy on cochlear implants (smb meeting)
190228 pitch student groep 2 diy on cochlear implants (smb meeting)
 
190129 presentatie stat stories lonneke opsteegh (smb meeting)
190129 presentatie stat stories   lonneke opsteegh (smb meeting)190129 presentatie stat stories   lonneke opsteegh (smb meeting)
190129 presentatie stat stories lonneke opsteegh (smb meeting)
 
190129 presentatie onder de bomen floris heukelom (smb meeting)
190129 presentatie onder de bomen   floris heukelom (smb meeting)190129 presentatie onder de bomen   floris heukelom (smb meeting)
190129 presentatie onder de bomen floris heukelom (smb meeting)
 
190129 de groeiversneller oost nl (smb meeting)
190129 de groeiversneller oost nl (smb meeting)190129 de groeiversneller oost nl (smb meeting)
190129 de groeiversneller oost nl (smb meeting)
 
190129 de groeiversneller oost nl (smb meeting)
190129 de groeiversneller oost nl (smb meeting)190129 de groeiversneller oost nl (smb meeting)
190129 de groeiversneller oost nl (smb meeting)
 
180927 presentation dhl ali kocer (smb hv meeting)
180927 presentation dhl ali kocer (smb hv meeting)180927 presentation dhl ali kocer (smb hv meeting)
180927 presentation dhl ali kocer (smb hv meeting)
 
180927 presentation enzyre waander van heerde (smb hv meeting)
180927 presentation enzyre waander van heerde (smb hv meeting)180927 presentation enzyre waander van heerde (smb hv meeting)
180927 presentation enzyre waander van heerde (smb hv meeting)
 
180927 presentation tjoapack dexter tjoa (smb hv meeting)
180927 presentation tjoapack dexter tjoa (smb hv meeting)180927 presentation tjoapack dexter tjoa (smb hv meeting)
180927 presentation tjoapack dexter tjoa (smb hv meeting)
 
180703 start updelta on tour slides smb meeting
180703 start updelta on tour slides smb meeting180703 start updelta on tour slides smb meeting
180703 start updelta on tour slides smb meeting
 
180703 sit and heat slides smb meeting
180703 sit and heat slides smb meeting180703 sit and heat slides smb meeting
180703 sit and heat slides smb meeting
 
180703 pink rf slides smb meeting
180703 pink rf slides smb meeting180703 pink rf slides smb meeting
180703 pink rf slides smb meeting
 
180222 presentatie orikami bram ten teuling (smb meeting)
180222 presentatie orikami bram ten teuling (smb meeting)180222 presentatie orikami bram ten teuling (smb meeting)
180222 presentatie orikami bram ten teuling (smb meeting)
 
180222 ru student presentation 4 nieuwe oren
180222 ru student presentation 4 nieuwe oren180222 ru student presentation 4 nieuwe oren
180222 ru student presentation 4 nieuwe oren
 
180222 ru student presentation 3 low key urine_screening
180222 ru student presentation 3 low key urine_screening180222 ru student presentation 3 low key urine_screening
180222 ru student presentation 3 low key urine_screening
 
180222 ru student presentation 2 object detection for hemispatial neglect pat...
180222 ru student presentation 2 object detection for hemispatial neglect pat...180222 ru student presentation 2 object detection for hemispatial neglect pat...
180222 ru student presentation 2 object detection for hemispatial neglect pat...
 
180222 ru student presentation 1 n ox measurement
180222 ru student presentation 1 n ox measurement180222 ru student presentation 1 n ox measurement
180222 ru student presentation 1 n ox measurement
 

Recently uploaded

Malaria Disease.pptx Department of Physiotherapy, SHUATS, Prayagraj
Malaria Disease.pptx Department of Physiotherapy, SHUATS, PrayagrajMalaria Disease.pptx Department of Physiotherapy, SHUATS, Prayagraj
Malaria Disease.pptx Department of Physiotherapy, SHUATS, PrayagrajSurabhi Srivastava
 
Anatomy of Female Reproductive System.pptx
Anatomy of Female Reproductive System.pptxAnatomy of Female Reproductive System.pptx
Anatomy of Female Reproductive System.pptxMathew Joseph
 
Disruption at the Neuromuscular Junction: Relevance of Autoantibodies to Ther...
Disruption at the Neuromuscular Junction: Relevance of Autoantibodies to Ther...Disruption at the Neuromuscular Junction: Relevance of Autoantibodies to Ther...
Disruption at the Neuromuscular Junction: Relevance of Autoantibodies to Ther...PeerVoice
 
Autism and Savant Syndrome|Study|The Good doctor .pptx
Autism and Savant Syndrome|Study|The Good doctor .pptxAutism and Savant Syndrome|Study|The Good doctor .pptx
Autism and Savant Syndrome|Study|The Good doctor .pptxScripted Symptoms
 
Ascariasis.pptx Department of Physiotherapy, SHUATS, Prayagraj
Ascariasis.pptx Department of Physiotherapy, SHUATS, PrayagrajAscariasis.pptx Department of Physiotherapy, SHUATS, Prayagraj
Ascariasis.pptx Department of Physiotherapy, SHUATS, PrayagrajSurabhi Srivastava
 
Analyzing Performance of the Twist Exome with CNV Backbone at Various Probe D...
Analyzing Performance of the Twist Exome with CNV Backbone at Various Probe D...Analyzing Performance of the Twist Exome with CNV Backbone at Various Probe D...
Analyzing Performance of the Twist Exome with CNV Backbone at Various Probe D...Golden Helix
 
RASASHALA IN ACCORDANCE WITH GMP....pptx
RASASHALA IN ACCORDANCE WITH GMP....pptxRASASHALA IN ACCORDANCE WITH GMP....pptx
RASASHALA IN ACCORDANCE WITH GMP....pptxDr. Anusha Baseganni
 
Poliomyelitis.pptx Department of Physiotherapy, SHUATS, Prayagraj
Poliomyelitis.pptx Department of Physiotherapy, SHUATS, PrayagrajPoliomyelitis.pptx Department of Physiotherapy, SHUATS, Prayagraj
Poliomyelitis.pptx Department of Physiotherapy, SHUATS, PrayagrajSurabhi Srivastava
 
PTERYGIUM ,clinical picture and its management.pptx
PTERYGIUM ,clinical picture and its management.pptxPTERYGIUM ,clinical picture and its management.pptx
PTERYGIUM ,clinical picture and its management.pptxvideosfildr
 
Materials for Spectacle Lenses​ UG STUDENTS.pptx
Materials for Spectacle Lenses​ UG STUDENTS.pptxMaterials for Spectacle Lenses​ UG STUDENTS.pptx
Materials for Spectacle Lenses​ UG STUDENTS.pptxKAUSAR NAHID
 
GROSS ANATOMY OF CAECUM & APPENDIX DR VKVS.ppt
GROSS ANATOMY OF CAECUM & APPENDIX DR VKVS.pptGROSS ANATOMY OF CAECUM & APPENDIX DR VKVS.ppt
GROSS ANATOMY OF CAECUM & APPENDIX DR VKVS.pptDr Vinay KV Shetty
 
Bioavailability & Bioequivalence Studies- Definitions, Methods of Measureme...
Bioavailability & Bioequivalence  Studies- Definitions, Methods  of Measureme...Bioavailability & Bioequivalence  Studies- Definitions, Methods  of Measureme...
Bioavailability & Bioequivalence Studies- Definitions, Methods of Measureme...Rajshri
 
Macquarie Neurosurgery Journal Club 2022 PPT
Macquarie Neurosurgery Journal Club 2022 PPTMacquarie Neurosurgery Journal Club 2022 PPT
Macquarie Neurosurgery Journal Club 2022 PPTMQ_Library
 
Physiology of Pituitary gland and its hormones -3.pptx
Physiology of Pituitary gland and its hormones -3.pptxPhysiology of Pituitary gland and its hormones -3.pptx
Physiology of Pituitary gland and its hormones -3.pptxSai Sailesh Kumar Goothy
 
JULIETH KABIRIGI,PAED.CARDIOLOGIST-CUHAS
JULIETH KABIRIGI,PAED.CARDIOLOGIST-CUHASJULIETH KABIRIGI,PAED.CARDIOLOGIST-CUHAS
JULIETH KABIRIGI,PAED.CARDIOLOGIST-CUHASJuliethKabirigi1
 
(DENGUE).pptx Department of Physiotherapy, SHUATS, Prayagraj
(DENGUE).pptx Department of Physiotherapy, SHUATS, Prayagraj(DENGUE).pptx Department of Physiotherapy, SHUATS, Prayagraj
(DENGUE).pptx Department of Physiotherapy, SHUATS, PrayagrajSurabhi Srivastava
 
CHRONIC IMMUNE-MEDIATED Demyelinating Neuropathies
CHRONIC IMMUNE-MEDIATED Demyelinating NeuropathiesCHRONIC IMMUNE-MEDIATED Demyelinating Neuropathies
CHRONIC IMMUNE-MEDIATED Demyelinating NeuropathiesMohamed AbdElhady
 
Measles.pptx Department of Physiotherapy, SHUATS, Prayagraj
Measles.pptx Department of Physiotherapy, SHUATS, PrayagrajMeasles.pptx Department of Physiotherapy, SHUATS, Prayagraj
Measles.pptx Department of Physiotherapy, SHUATS, PrayagrajSurabhi Srivastava
 

Recently uploaded (20)

Malaria Disease.pptx Department of Physiotherapy, SHUATS, Prayagraj
Malaria Disease.pptx Department of Physiotherapy, SHUATS, PrayagrajMalaria Disease.pptx Department of Physiotherapy, SHUATS, Prayagraj
Malaria Disease.pptx Department of Physiotherapy, SHUATS, Prayagraj
 
Anatomy of Female Reproductive System.pptx
Anatomy of Female Reproductive System.pptxAnatomy of Female Reproductive System.pptx
Anatomy of Female Reproductive System.pptx
 
Disruption at the Neuromuscular Junction: Relevance of Autoantibodies to Ther...
Disruption at the Neuromuscular Junction: Relevance of Autoantibodies to Ther...Disruption at the Neuromuscular Junction: Relevance of Autoantibodies to Ther...
Disruption at the Neuromuscular Junction: Relevance of Autoantibodies to Ther...
 
Autism and Savant Syndrome|Study|The Good doctor .pptx
Autism and Savant Syndrome|Study|The Good doctor .pptxAutism and Savant Syndrome|Study|The Good doctor .pptx
Autism and Savant Syndrome|Study|The Good doctor .pptx
 
eye disorders .pptx
eye disorders .pptxeye disorders .pptx
eye disorders .pptx
 
Ascariasis.pptx Department of Physiotherapy, SHUATS, Prayagraj
Ascariasis.pptx Department of Physiotherapy, SHUATS, PrayagrajAscariasis.pptx Department of Physiotherapy, SHUATS, Prayagraj
Ascariasis.pptx Department of Physiotherapy, SHUATS, Prayagraj
 
Analyzing Performance of the Twist Exome with CNV Backbone at Various Probe D...
Analyzing Performance of the Twist Exome with CNV Backbone at Various Probe D...Analyzing Performance of the Twist Exome with CNV Backbone at Various Probe D...
Analyzing Performance of the Twist Exome with CNV Backbone at Various Probe D...
 
RASASHALA IN ACCORDANCE WITH GMP....pptx
RASASHALA IN ACCORDANCE WITH GMP....pptxRASASHALA IN ACCORDANCE WITH GMP....pptx
RASASHALA IN ACCORDANCE WITH GMP....pptx
 
Poliomyelitis.pptx Department of Physiotherapy, SHUATS, Prayagraj
Poliomyelitis.pptx Department of Physiotherapy, SHUATS, PrayagrajPoliomyelitis.pptx Department of Physiotherapy, SHUATS, Prayagraj
Poliomyelitis.pptx Department of Physiotherapy, SHUATS, Prayagraj
 
PTERYGIUM ,clinical picture and its management.pptx
PTERYGIUM ,clinical picture and its management.pptxPTERYGIUM ,clinical picture and its management.pptx
PTERYGIUM ,clinical picture and its management.pptx
 
Materials for Spectacle Lenses​ UG STUDENTS.pptx
Materials for Spectacle Lenses​ UG STUDENTS.pptxMaterials for Spectacle Lenses​ UG STUDENTS.pptx
Materials for Spectacle Lenses​ UG STUDENTS.pptx
 
A case of Trichobezoar in a teenage female
A case of Trichobezoar in a teenage femaleA case of Trichobezoar in a teenage female
A case of Trichobezoar in a teenage female
 
GROSS ANATOMY OF CAECUM & APPENDIX DR VKVS.ppt
GROSS ANATOMY OF CAECUM & APPENDIX DR VKVS.pptGROSS ANATOMY OF CAECUM & APPENDIX DR VKVS.ppt
GROSS ANATOMY OF CAECUM & APPENDIX DR VKVS.ppt
 
Bioavailability & Bioequivalence Studies- Definitions, Methods of Measureme...
Bioavailability & Bioequivalence  Studies- Definitions, Methods  of Measureme...Bioavailability & Bioequivalence  Studies- Definitions, Methods  of Measureme...
Bioavailability & Bioequivalence Studies- Definitions, Methods of Measureme...
 
Macquarie Neurosurgery Journal Club 2022 PPT
Macquarie Neurosurgery Journal Club 2022 PPTMacquarie Neurosurgery Journal Club 2022 PPT
Macquarie Neurosurgery Journal Club 2022 PPT
 
Physiology of Pituitary gland and its hormones -3.pptx
Physiology of Pituitary gland and its hormones -3.pptxPhysiology of Pituitary gland and its hormones -3.pptx
Physiology of Pituitary gland and its hormones -3.pptx
 
JULIETH KABIRIGI,PAED.CARDIOLOGIST-CUHAS
JULIETH KABIRIGI,PAED.CARDIOLOGIST-CUHASJULIETH KABIRIGI,PAED.CARDIOLOGIST-CUHAS
JULIETH KABIRIGI,PAED.CARDIOLOGIST-CUHAS
 
(DENGUE).pptx Department of Physiotherapy, SHUATS, Prayagraj
(DENGUE).pptx Department of Physiotherapy, SHUATS, Prayagraj(DENGUE).pptx Department of Physiotherapy, SHUATS, Prayagraj
(DENGUE).pptx Department of Physiotherapy, SHUATS, Prayagraj
 
CHRONIC IMMUNE-MEDIATED Demyelinating Neuropathies
CHRONIC IMMUNE-MEDIATED Demyelinating NeuropathiesCHRONIC IMMUNE-MEDIATED Demyelinating Neuropathies
CHRONIC IMMUNE-MEDIATED Demyelinating Neuropathies
 
Measles.pptx Department of Physiotherapy, SHUATS, Prayagraj
Measles.pptx Department of Physiotherapy, SHUATS, PrayagrajMeasles.pptx Department of Physiotherapy, SHUATS, Prayagraj
Measles.pptx Department of Physiotherapy, SHUATS, Prayagraj
 

160929 roche presentation molecule to business

  • 1. How to deal with the affordability of oncology drugs? From personalised medicine to personalised reimbursement models Jeroen van Dijk, Sales Director, Roche Nederland September 29th 2016
  • 2. Doing now what patients need next
  • 3. Political and public discussions Bron: www.minvws.nl; KWF, 2015
  • 4. The Netherlands compared to other EU countries Source: Healthcare costs of cancer per person in European Union (Luengo-Fernandez et al - Lancet Oncology, 2013)
  • 5. Spending over the last years Out-patient vs hospital setting Outpatient drugs Hospital drugs Spending in bln €
  • 6. Drug expenses in 2015 Health care expenses 2015 Increase Health care budget (Budget Kader Zorg) €73 billion - Drugs (total) €5 billion 6% Inpatient drugs €2.06 billion 6% ‘Expensive’ inpatient drugs €1.62 billion 9% ‘Expensive’ oncology drugs €810 million 15% Source: Farminform, 2016
  • 7. Budget cap for hospitals Maximum growth 1% per annum • Agreement between MoH, NVZ, NFU, NPCF, ZKN, ZN, OMS. • Cap on growth rate: • 2012-2013: 2,5% p.a. • 2014: 1,5% p.a. • 2015-2017: 1% p.a. Healthcare Insurance Act € 45,9 billion Longterm care € 19,9 billion Wmo € 6,7 billion Other € 0,4 billion NationalHealthcareBudget:€72,9billion Hospital care € 23,0 billion (Incl. hospital drugs) Ref: National Budget 2016 (2015); Administrative Agreement 2012, 2013 Outpatient drugs
  • 8. Sounding the alarm on drug prices
  • 9. Pricing by Roche Roche only develops innovative drugs Population size ValueR&D • Drug prices depend on economic situation, governmental priorities and health care system • Therefore differentiation of drug prices among EU countries is crucial for the accessibility to drugs for patients in Europe
  • 10. How to warrant affordability and accessibility in the future? Are we not able to pay for it or we just don’t know how? • Several measures are used in the NL to maintain affordability and accessibility in the future, such as: – Rational pharmacotherapy (‘gepast gebruik’) • E.g. Start-stop criteria – Financial arrangements to constrain the budget impact • Initiated by Ministry of Health (‘buro prijsarrangementen geneesmiddelen’) – Value-based health care • Cost-effectiveness
  • 11. Is a fixed CE-threshold is appropriate for decision making? Metastatic versus early setting • First introduction of new oncology drugs is in metastatic setting • According to current models used, the ‘value’ of the drug is always lower here compared to the early setting* • Is that right? • What does a cost per QALY mean in the metastatic setting? • What does this mean for price setting? *Dvortsin et al. PLoS ONE 11(1): e0146551. doi:10.1371
  • 12. How to optimize ‘value’? • Increase in value – Personalised medicine • Biomarker testing • Rational pharmacotherapy agreements • How to measure value – Gather Real World Evidence • Clinical outcomes – Value for society Personalised medicines  personalised reimbursement models
  • 13. Challenge: future combination therapies • Expected Combination Regimen Launches in Oncology
  • 14. Drugs of different companies being combined • Potential Combination Therapies Launching by 2021
  • 15. From volume to value Increasing levels of patient based information Undifferentiated price per vial Episode-of- care Unit based pricing Personalised Reimbursement Models Today Future Combinations + Reimbursement driven by volume of therapy used Reimbursement driven by value therapy delivers to the patient National registries Multiple indications Pay for response ?
  • 16. Takeaways • A fixed cost-effectiveness threshold for drugs in the metastatic setting is not desirable • Personalised medicine asks for personalised reimbursement models – Nationwide registries warranted – How to deal with combination therapies? • Collaboration between all relevant stakeholders needed in order to keep the health care system affordable and sustainable
  • 17. Doing now what patients need next